Expert Financial Analysis and Reporting

If you haven’t already seen it, there is video posted on You Tube in which a key opinion leader (KOL) made some brief comments on DCVax-L. See this link.  Note that comments on DCVax-L start at about 1:45 in. The KOL was Dr. Steven Brem, Professor of Neurosurgery, Chief Neurosurgical Oncology, Co-Director Penn Brain Tumor […]

Introduction This report addresses three issues: The capability of the Sawston UK plant to manufacture Northwest Biotherapeutics’ dendritic cell vaccine in accordance with regulatory requirements and to scale up to manufacture it in substantial quantities. (Note that in the US, this product is referred to as DCVax-L, but may go by a different brand name(s) […]

Investment Thinking The fourth quarter conference call was very encouraging to me. The investment thesis is coming together much better and faster than I had hoped a year or so ago. Total sales for 2020 increased by 21%% to $149.6 million and the Company is guiding to a 17 to 33% increase in 2021 to […]

Investment Thinking I believe that the stock of Cryoport can deliver exceptional returns over the next five, ten or more years. The current correction in the stock off of its January 22, 2021 high of $82.11 is disheartening, although these types of periodic corrections are inevitable in an investor’s life. You probably want to know […]

Investment Overview I first recommended Repligen in an initiation report published on December 4, 2012  at a price of $6.12. Now selling at a price of $223, it has been a good recommendation. My original reason for recommending the stock was that its business model was to support manufacturing of biologics and in particular monoclonal […]

Introduction I have shut down the subscription service for SmithOnStocks and have refunded subscription fees for those subscribers who paid their annual subscription fee in the period from August 2020 to February 2021. My payments provider, PayPal, didn’t allow for refunds to subscribers who paid in the March 2020 to July 2020 period. Those subscribers […]

Cancer Concerns About bluebird bio’s Gene Therapy Products bluebird bio announced a temporary suspension of two trials of its  LentiGlobin gene therapy for sickle cell disease (SCD) and also the suspension of marketing of a different gene therapy, Zynteglo, in Europe. The reason was a report that a sickle cell patient who was treated more […]

The media focus on corrupt hedge fund short selling has not surprisingly turned to bloggers who are closely associated with short selling. The first casualty has been Andrew Left of Citron Research who was leading the charge on shorting GameStop and got hammered on his short position. The Wall Street Journal reports  that his firm […]

The Current Media Narrative That Retail Investors Trading on Robinhood Were Primarily Responsible for the GameStop Short Squeeze Appears False. It Was More Likely Orchestrated by Hedge Funds Key Thoughts Mainstream media is treating the GameStop short squeeze as a new phenomenon in which free online trading on platforms like Robinhood has led to excessive […]

It is Time for Wall Street Wall Street Business Practices to Be Disrupted The frenzy of news flow around the short squeeze on GameStop might be viewed as some kind of one off, weird trading situation precipitated by retail speculators. Old Wall Street hands are saying that it will pass, although they also suggest that […]